RICERCA ITALIANA     

FIRB simili:

• 1 - Progettazione, sintesi e screening biologico con metodi ad alta resa di librerie combinatoriali di molecole sviluppate a partire da unità strutturali originali, per applicazioni in campo terapeutico e diagnostico
• 2 - Il riconoscimento molecolare nelle interazioni proteina-ligando, proteina-proteina e proteina superficie: sviluppo di approcci sperimentali e computazionali integrati per lo studio di sistemi di interesse farmaceutico
• 3 - Sviluppo di molecole innovative in grado di curare malattie neurodegenerative e neuroinfiammatorie.
• 4 - NANOTECNOLOGIE E NANOSCIENZE ORGANICHE
• 5 - Metodologie per l'individuazione e lo sviluppo di molecole in grado di interferire specificamente con bersagli critici per la terapia di malattie
• 6 - Molecole innovative ad attività antiflogistica ed antitumorale prodotte con metodologie chimiche avanzate
• 7 - Sviluppo di Tecnologie Avanzate per lo Studio della Proteomica Differenziale del Segnale (Segnalo-Proteomica)
• 8 - Sviluppo di microsistemi multifunzionali per analisi in diagnostica clinica e nel settore alimentare
• 9 - Metodologie Innovative di Risonanza Magnetica (RM) in Patologie Tumorali e Cardiovascolari
• 10 - MALATTIE NEURODEGENERATIVE COME CONSEGUENZA DI UN ALTERATO PROCESSAMENTO DI PROTEINE NEURONALI. MODELLI ANIMALI E DI COLTURE CELLULARI IN VITRO.

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze chimiche
  • CHIMICA FARMACEUTICA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)
  • ORGANIC CHEMISTRY (such compounds as the oxides, sulfides, or oxysulfides of carbon, cyanogen, phosgene, hydrocyanic acid or salts thereof C01; products obtained from layered base-exchange silicates by ion-exchange with organic compounds such as ammonium, phosphonium or sulfonium compounds or by intercalation of organic compounds C01B33/44; macromolecular compounds C08; dyes C09; fermentation products C12; fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture C12P; production of organic compounds by electrolysis or electrophoresis C25B3/00, C25B7/00)
    • PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

Classificazione geografica

• Regione: Emilia Romagna

Bibliografia

1. Lindsay MA Target discovery. Nat Rev Drug Discov. 2003;2:831-838.
2. Brekke OH, Sandlie I Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov. 2003;2:52-62.
3. Lin J, Sahakian DC, de Morais SM, Xu JJ, Polzer RJ, Winter SM The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. Curr Top Med Chem. 2003;3:1125-1154.
4. Wang W, Donini O, Reyes CM, Kollman PA Biomolecular simulations: recent developments in force fields, simulations of enzyme catalysis, protein-ligand, protein-protein, and protein-nucleic acid noncovalent interactions. Annu Rev Biophys Biomol Struct. 2001;30:211-243.
5. Carloni P, Rothlisberger U, Parrinello M The role and perspective of ab initio molecular dynamics in the study of biological systems. Acc Chem Res. 2002;35:455-464.
6. Warshel A Computer simulations of enzyme catalysis: methods, progress, and insights. Annu Rev Biophys Biomol Struct. 2003;32:425-443.
7. Lyne PD Structure-based virtual screening: an overview. Drug Discov Today. 2002;7:1047-1055.
8. Gallop MA, Barrett RW, Dower WJ, Fodor SP, Gordon EM Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries. J Med Chem. 1994;37:1233-1251.
9. Gordon EM, Barrett RW, Dower WJ, Fodor SP, Gallop MA Applications of combinatorial technologies to drug discovery. 2. Combinatorial organic synthesis, library screening strategies, and future directions. J Med Chem. 1994;37:1385-1401.
10. Borman S Reducing time to drug discovery. Chem Eng News. 1999;77:33-48.
11. Borman S The many faces of combinatorial chemistry. Chem Eng News. 2003;81:45-56.
12. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS, Whitlow M Single-chain antigen-binding proteins. Science. 1988;242:423-6.
13. WinterG, Griffiths AD, Hawkins RE, Hoogenboom HR Making antibodies by phage display technology. Annu Rev Immunol. 1994;12:433-455.
14. Andrisano V, Bartolini M, Gotti R, Cavrini V, Felix G Immobilized receptor- and transporter-based liquid chromatographic phases for on-line pharmacological and biochemical studies: a mini-review, J Chromatogr B. 2001;753:375-383
15. Moaddel R, Lu L, Baynham M, Wainer IW Immobilized receptor- and transporter-based liquid chromatographic phases for on-line pharmacological and biochemical studies: a mini-review, J Chromatogr B. 2002;768:41.
16. Bertucci C, Petri A, Felix G, Perini B, Salvadori P Lipase-based HPLC stationary phase: enantioselective synthesis of 2-substituted 1,3-propanediol monoacetates. Tetrahedron Asymmetry. 1999;10:4455.
17. Pasternyk M, Ducharme MP, Descorps V, Felix G, Wainer IW On-line deconjugation of chloramphenicol-beta-D-glucuronide on an immobilized beta-glucuronidase column. Application to the direct analysis of urine samples, J Chromatogr A. 1998;828:135.
18. Podgornik A, Tennikova TB Chromatographic reactors based on biological activity, Adv Biochem Eng Biotechnol. 2002; 76:165-210.
19. Bertucci C, Bartolini M, Gotti R, Andrisano V Drug affinity to immobilized target bio-polymers by high performance liquid chromatography and capillary electrophoresis. J Chromat B. 2003;797:111-129.
20. Bertucci C, Domenici E Reversible and covalent binding of drugs to human serum albumin: methodological approache and physiological relevance. Curr Med Chem. 2002;9:1463.
21. Wilson WD Analyzing biomolecular interactions, Science. 2002;295:2103-2105.
22. Weimar T Recent trends in the application of evanescent wave biosensors, Angew Chem Int Ed Engl. 2000; 39:1219-1221.
23. Rossi JJ Ribozymes in the nucleolus. Science. 1999;285:1685.
24. Fire A RNA-triggered gene silencing. Trends Genet. 1999;15:358-363.
25. Tavernarakis N, Wang SL, Dorovkov M, Ryazanov A, Driscoll M Heritable and inducible genetic interference by double-stranded RNA encoded by transgenes. Nat Genet. 2000;24:180-183.
27. Biocca S, Neuberger MS, Cattaneo A. Expression and targeting of intracellular antibodies in mammalian cells. EMBO J. 1990;9:101-108.
27. Cattaneo A, Biocca S Intracellular Antibodies: Development and Applications (1997).
28. Hiatt A, Cafferkey R, Bowdish K et al. Production of antibodies in transgenic plants. Nature. 1989;342:76-78.
29. Tavladoraki P, Benvenuto E, Trinca S, De Martinis D, Cattaneo A, Galeffi P Transgenic plants expressing a functional "single chain Fv" antibody are specifically protected from virus attack. Nature. 1993;366:469-472.
30. Michaelis ML Drugs targeting Alzheimer’s disease: some things old and some things new. J Pharmacol Exp Ther. 2003;304:897-904.
31. Nunoruma A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2001;60 :759-767.
32. Lad SP, Neet KE, Mufson EJ Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease. Curr Drug Target CNS Neurol Disord. 2003;2:315-334.
33. Lau SF, Schachter JB, Seymour PA Sanner MA Tau protein phosphorylation as a therapeutic target in Alzheimer’s disease. Curr Top Med Chem. 2002;2:395-415.
34. Messer WS Jr. Cholinergic agonists and the treatment of Alzheimer’s disease. Curr Top Med Chem. 2002;2:353-358.
35. Inestrosa NC, Alvarez A, Perez CA, Moreno RD, Vicente M, Linker C, Casanueva OI, Soto C, Garrido J. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron. 1996;16:881-891.
36. Rees T, Hammond PI, Soreq H, Younkin S, Brimijoin S. Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. Neurobiol Aging. 2003;24:777-787.
37. Recanatini M, Cavalli A. Acetylcholinesterase inhibitors in the context of therapeutic strategies to combat Alzheimer's disease. Expert Opin Ther Pat .2002;12:1853-1865.
38. Melchiorre C, Andrisano V, Bolognesi ML, Budriesi R, Cavalli A, Cavrini V, Rosini M, Tumiatti V, Recanatini M. Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease. J Med Chem. 1998;41:4186-4189.
39. Piazzi L, Rampa A, Bisi A, Gobbi S, Belluti F, Cavalli A, Bartolini M, Andrisano V, Valenti P, Recanatini M. 3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. J Med Chem. 2003;46:2279-2282.
40. Romanelli MN, Gualtieri F. Cholinergic nicotinic receptors: competitive ligands, allosteric modulators, and their potential applications. Med Res Rev. 2003;23:393-426.
41. Imahori K, Hoshi M, Ishiguro K, Sato K, Takahashi M, Shiurba R, Yamaguchi H, Takashima A, Uchida T. Possible role of tau protein kinases in pathogenesis of Alzheimer’s disease. Neurobiol Aging. 1998;19:S93-S98.
42. Patrick GN, Zuckerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai L-H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 1999;402:615-622.
43. Selkoe DJ. Introducing transglutaminase into the study of Alzheimer’s disease. A personal look back. Neurochem Internat. 2002;40:13-16.
44. Capsoni S, Ugolini G, Comparini A, Ruberti F, Berardi N, Cattaneo A. Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc Natl Acad Sci USA. 2000;97:6826-31.
45. Capsoni S, Giannotta S, Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci USA. 2002;99:12432-12437.

Parole Chiave

malattia di Alzheimer; antiossidanti; progettazione molecolare; identificazione del lead; screening ad alta resa e virtuale; ADMET